The first results of using «3D» interferon-free therapy in real clinical practice in Russia: the experience of the Kirov Region


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Nowadays interferon-free therapy for chronic hepatitis C is being increasingly introduced into clinical practice worldwide. Due to its high efficiency and favorable safety profile, the therapy can be a treatment for advanced stages of the disease, including obvious liver fibrosis and cirrhosis. The use of traditional IFN-containing regimens in this patient category is problematic due to their limited efficiency and high risk of adverse events. The first interferon-free combination registered in Russia in April 2015 was 3D regimen containing 3 direct-acting antivirals: paritaprevir (a protease inhibitor), ombitasvir (a NS5A protein inhibitor), and dasabuvir (a polymerase inhibitor). The article describes the first experience with 3D interferon-free therapy in 30 patients with advanced-stage of liver fibrosis and cirrhosis in the Kirov Region.

Full Text

Restricted Access

About the authors

E. G Tikhomolova

Kirov Clinical Hospital for Infectious Diseases

Email: e.tikhomolova@mail.ru. kikb43@rambler.ru

A. A Osokina

Kirov Clinical Hospital for Infectious Diseases

Email: Allao08@mail.ru

D. A Matveev

Ministry of Health of the Kirov Region

Email: matveev@ako.kirov.ru
Kirov

E. D Utemova

Ministry of Health of the Kirov Region

Email: ip-depart@medstat.kirov.ru
Kirov

N. V Kulikova

Kirov Regional Territorial Compulsory Health Insurance Fund

Email: kotfoms@kotfoms.kirov.ru

E. A Fursova

Kirov Clinical Hospital for Infectious Diseases

Email: Kikb43@rambler.ru

V. I Zhuikova

Kirov Clinical Hospital for Infectious Diseases

Email: kikb43@rambler.ru

References

  1. Guidelines for the screening, care and treatment of persons with hepatitis C infection. http://www.who.int/hiv/pub/hepatitis/hepatitis-c-guidelines/en/
  2. WHO Hepatitis C Fact sheet № 164. http://www.who.int/mediacen-tre/ factsheets/fs164/en/
  3. Freeman A.J., Dore G.J., Law M.G., Thorpe M., Von Overbeck J., Lloyd A.R., Marinos G., Kaldor J.M. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001; 34: 809-816 [PMID: 11584380 DOI: 10.1053/ jhep.2001.27831].
  4. Fried M.W. Side effects of therapy of hepatitis C and the irmanagement. Hepatology 2002; 36: 237-244.
  5. Sulkowski M.S., Cooper C., Hunyady B., Jia J., Ogurtsov P., Peck-Radosavljevic M., Shiffman M.L., Yurdaydin C., Dalgard O. Management of adverse effects of Peg-IFN and ribavirintherapy for hepatitis C. Nat. Rev. Gastroenterol. Hepatol. 2011; (8): 212-223.
  6. Noureddin M., Ghany M.G. Pharmacokinetics andpharmacodynamics of peginterferon and ribavirin:implications for clinical efficacy in the treatment of chronichepatitis C. Gastroenterol. Clin. North. Am. 2010; 39: 649-658.
  7. Reddy K.R., Nelson D.R., Zeuzem S. Ribavirin: current role in the optimal clinical management of chronic hepatitis C. J. Hepatol. 2009; 50: 402-411.
  8. Cooper C.L., Druyts E., Thorlund K., Nachega J.B., El Khoury A.C., O’Regan C., Mills E.J. Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: an indirect comparison meta-analysis. Therapeutics and Clinical Risk Management 2012: (8); 105-130.
  9. Инструкция по применению боцепревира FDA. http://www. accessdata.fda.gov/drugsatfda_docs/label/2011/202258lbl.pdf
  10. Инструкция по применению телапревира FDA. http://www. accessdata.fda.gov/drugsatfda_docs/label/2011/201917lbl.pdf
  11. Zeuzem S., Andreone P., Pol S., Lawitz E, Diago M, Roberts S., Focaccia R., Younossi Z., Foster G.R., Horban A., Ferenci P., Nevens F., Müllhaupt B., Pockros P., Terg R., Shouval D., van Hoek B., Weiland O., Van Heeswijk R., De Meyer S., Luo D., Boogaerts G., Polo R., Picchio G., Beumont M.; REALIZE Study Team. Telaprevir for retreatment of HCV infection. N. Engl. J. Med. 2011; 364: 2417-2428. doi: 10.1056/NEJMoa1013086
  12. Vierling J.M., Helmond F.A., Wahl J. Sustained Virologic Response (SVR) in Prior Peginterferon/Ribavirin (PR) Treatment Failures After Retreatment With Boceprevir (BOC) PR: Final Results of the Provide Study. Digestive Disease Week (DDW 2013). Orlando, May 18-21, 2013. Abstract 869 р.
  13. Бацких С.Н. Безинтерфероновая терапия хронического гепатита С: смена препаратов или новая парадигма лечения? Рос. журн. гастроэнтерол., гепатол, колопроктол. 2014; (4): 23-31.
  14. Регистрационное удостоверение препарата Викейра Пак ЛП-002965 от 21.04.2015. grls.rosminzdrav.ru
  15. Российская инструкция по применению препарат Викейра Пак grls.rosminzdrav.ru
  16. SmPC от 09.03.2015 (Европейское агентство по оценке лекарственных средств). http://ec.europa.eu/health/documents/ community-register/2015/ 20150115130406/anx_130406_en.pdf
  17. Kumada H., Chayama K., Rodrigues L. Jr., Suzuki F., Ikeda K., Toyoda H., Sato K., Karino Y., Matsuzaki Y., Kioka K., Setze C., Pilot-Matias T., Patwardhan M., Vilchez R.A., Burroughs M., Redman R. Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis. Hepatology 2015; 62(4): 1037-1046.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies